The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Nataliya Mar discussing real world toxicity profile of enfortumab vedotin with or without pembrolizumab in ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

It was there that a biopsy uncovered the truth: Armando had Stage 4 metastatic urothelial carcinoma (mUC), also known as advanced bladder ... Exploring PADCEV (enfortumab vedotin-ejfv) with ...